Search Results
Your search for Saad Usmani, MD matches 31 pages
Showing 1 - 31Newly Diagnosed Multiple Myeloma
“Ask yourself at every moment, ‘Is this necessary?’” —Marcus Aurelius To complement The ASCO Post’s extensive coverage of the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, here are two important abstracts selected from the meeting proceedings focusing on induction and...
Bispecific Antibodies and the Dawn of a New Era in Treatment of Multiple Myeloma
“I think the biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning!” —Steve Jobs Relapsed and refractory multiple myeloma remains a treatment challenge. Promising responses have been demonstrated with bispecific antibodies, with a...
MajesTEC-1: Bispecific Antibody Teclistamab for Relapsed or Refractory Multiple Myeloma
In the phase I/II MajesTEC-1 trial presented at the 2022 ASCO Annual Meeting (Abstract 8007) and simultaneously published in The New England Journal of Medicine, Philippe Moreau, MD, and colleagues found that the bispecific antibody teclistamab produced responses in nearly two-thirds of patients...
Continued Progression-Free Survival Benefit With Carfilzomib/Dexamethasone/Daratumumab vs Carfilzomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma
In an updated analysis of the pivotal phase III CANDOR trial reported in The Lancet Oncology, Saad Z. Usmani, MD, of Levine Cancer Institute/Atrium Health, and colleagues found that the addition of daratumumab to carfilzomib and dexamethasone (KdD) continued to show a large progression-free...
CANDOR: Continued Progression-Free Survival Benefit With Carfilzomib, Dexamethasone, and Daratumumab vs Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
In an updated analysis of the pivotal phase III CANDOR trial reported in The Lancet Oncology, Saad Z. Usmani, MD, and colleagues found that the addition of daratumumab to carfilzomib and dexamethasone (KdD) continued to show a large progression-free survival benefit in patients with relapsed or...
MSK Appoints Saad Z. Usmani, MD, MBA, FACP, Chief of Myeloma Service
Physician leader and clinical and translational investigator Saad Z. Usmani, MD, MBA, FACP, recently joined Memorial Sloan Kettering Cancer Center (MSK) as Chief of Myeloma Service. He was also appointed Professor at the Joan & Sanford I. Weill Medical College of Cornell University. Dr....
High-Risk Multiple Myeloma: Combination Regimens and CAR T-Cell Therapy
“Continuous improvement is better than delayed perfection.” —Mark Twain To complement The ASCO Post’s extensive coverage of the 2021 ASCO Annual Meeting, here are several abstracts selected from the meeting proceedings focusing on novel treatments under study in high-risk multiple myeloma. For...
Saad Z. Usmani, MBA, MD, on Multiple Myeloma: Updated Results From the CARTITUDE-1 Study of Ciltacabtagene Autoleucel
Saad Z. Usmani, MBA, MD, of the Levine Cancer Institute, discusses new data on the CAR T-cell therapy ciltacabtagene autoleucel, a single infusion of which yielded early, deep, and durable responses in heavily pretreated patients with relapsed or refractory multiple myeloma (Oral Abstract MM-119).
Teclistamab Shows Efficacy, Produces Durable Responses in Relapsed or Refractory Multiple Myeloma
In a phase I trial (MajesTEC-1) reported in The Lancet, Saad Z. Usmani, MD, FACP, and colleagues found that the B-cell maturation antigen (BCMA)-CD3 bispecific antibody teclistamab produced a high rate of durable responses at the recommended phase II dose in patients with relapsed or refractory...
IMF Launches Initiative to Improve Outcomes in Multiple Myeloma Among Black Americans
The International Myeloma Foundation (IMF) has begun a multiyear, multidisciplinary initiative, M-Power Charlotte, which is designed to promote the early diagnosis and treatment of myeloma in the Black community. The IMF is working with Atrium Health Levine Cancer Institute’s Disparities &...
FDA Approves Daratumumab Plus Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
On August 20, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex) in combination with carfilzomib (Kyprolis) and dexamethasone (DKd) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three previous lines of therapy....
CANDOR Trial: Carfilzomib, Dexamethasone, and Daratumumab vs Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
As reported in The Lancet by Meletios Dimopoulos, MD, and colleagues, the phase III CANDOR trial has shown prolonged progression-free survival with carfilzomib, dexamethasone, and daratumumab (KdD) vs carfilzomib and dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma....
Elotuzumab Fails to Add Benefit in Newly Diagnosed High-Risk Myeloma
The addition of elotuzumab to a standard three-drug induction regimen did not improve outcomes in patients with high-risk multiple myeloma enrolled in the randomized phase II SWOG S1211 trial, according to findings reported during the ASCO20 Virtual Scientific Program by Saad Zafar Usmani, MD,...
Cancer and COVID-19: Considerations About Neutropenia, Anemia, and Thrombocytopenia
GUEST EDITORS Dr. Abutalib is Associate Director of the Hematology and Cellular Therapy Program and Director of the Clinical Apheresis Program at Cancer Treatment Centers of America, Zion, Illinois; Associate Professor at the Roseland Franklin University of Medicine and Science; and Founder and...
Saad Z. Usmani, MD: In My Experience Question 5
For community oncologists treating patients with multiple myeloma during the COVID-19 pandemic, what resources and clinical pearls would you suggest? Recorded April 24, 2020.
Saad Z. Usmani, MD: In My Experience Question 4
For patients with multiple myeloma who are currently on clinical trials, what are the most pressing issues as we fight COVID-19? Recorded April 24, 2020.
Saad Z. Usmani, MD: In My Experience Question 3
Because of the COVID-19 pandemic, has your management strategy changed for post-transplant consolidation and maintenance therapy in patients with multiple myeloma? Recorded April 24, 2020.
Saad Z. Usmani, MD: In My Experience Question 2
During the COVID-19 pandemic, do you suggest delaying upfront autologous transplant for patients with multiple myeloma? Recorded April 24, 2020.
Saad Z. Usmani, MD: In My Experience Question 1
As a result of COVID-19, has your decision model for front-line therapy changed for patients with multiple myeloma who are either transplant-eligible or ineligible? Recorded April 24, 2020.
Continuous Coverage of COVID-19
The staff of The ASCO Post recognizes the steady flow of news on the novel coronavirus, or COVID-19. Here, we've compiled a list of links to articles and resources on the COVID-19 pandemic. If you have a report you'd like to share, please e-mail it to us at editor@ascopost.com. Direct From ASCO:...
Highlights From ASH 2019 Included New Data in Leukemia, Lymphoma, and Multiple Myeloma
The ASH 2019 Annual Meeting & Exposition featured countless important sessions and lectures. It would be impossible to attend all the symposia, oral presentations, poster presentations, and special events. Below, we have selected some presentation highlights to supplement our coverage of the...
Conference Highlights From the 2019 American Society of Hematology Annual Meeting & Exposition
More than 25,000 specialists in hematology from over 115 countries attended the 61st American Society of Hematology (ASH) Annual Meeting & Exposition held last December in Orlando. The conference featured a stunning array of 4,900 abstracts with impressive new data in the treatment of multiple...
Saad Z. Usmani, MD, on Carfilzomib, Dexamethasone, and Daratumumab for Relapsed or Refractory Myeloma
Saad Z. Usmani, MD, of the Levine Cancer Institute, discusses phase III study findings suggesting that the combination of carfilzomib/dexamethasone/daratumumab represents an efficacious new regimen for patients with relapsed or refractory disease, including those refractory to lenalidomide...
Addition of Daratumumab Increases Benefit of Carfilzomib/Dexamethasone in Multiple Myeloma
In patients with relapsed or refractory multiple myeloma, the addition of daratumumab to carfilzomib plus dexamethasone improved multiple outcomes, compared with carfilzomib/dexamethasone alone, in the international phase III CANDOR trial.1 “Overall, carfilzomib/dexamethasone/daratumumab was...
Selinexor/Dexamethasone in Refractory Multiple Myeloma: The STORM Has Arrived, but Does It Represent Climate Change?
The term “relapsed/refractory multiple myeloma” is often used to describe advanced myeloma that has progressed through primary or salvage therapy. The International Myeloma Working Group (IMWG) defined the term in 2011 as disease that is “nonresponsive while on salvage therapy or progresses...
Expert Point of View: Ravi Vij, MD and Saad Usmani, MD
Ravi Vij, MD, Professor of Medicine at Washington University School of Medicine, St. Louis, and Saad Usmani, MD, Director of Plasma Cell Disorders at Levine Cancer Institute, Charlotte, North Carolina, spoke to The ASCO Post about the studies presented on chimeric antigen receptor (CAR) T-cell...
I Plan to Live Long Enough to Be Cured of Multiple Myeloma
Like many other patients diagnosed with multiple myeloma, I didn’t know I had the cancer until I broke a bone. I had felt a twinge of pain on my left side when I hoisted a bucket of baseballs over my left shoulder after participating in a baseball tournament in the spring of 2011, but there was...
Saad Usmani, MD, on Daratumumab as Monotherapy for Multiple Myeloma
For a heavily pretreated multiple myeloma population, daratumumab as a monotherapy showed meaningful, durable activity with deep responses and a favorable safety profile. Saad Usmani, MD, of the Levine Cancer Institute, provides the highlights of this study on the first monoclonal antibody to show...
2015 ASCO Annual Meeting Planning Committees
The ASCO Annual Meeting highlights the latest research and treatment advances in oncology, with more than 28,000 oncology professionals attending each year. ASCO wishes to acknowledge the volunteers on this year’s Cancer Education and Scientific Program Committees, and thank them for their time and ...
Impressive Results With Daratumumab Plus Lenalidomide/Dexamethasone in Multiple Myeloma
The anti-CD38 monoclonal antibody daratumumab (Darzalex) took center stage among multiple myeloma studies presented at the 57th American Society of Hematology Annual Meeting and Exposition. In relapsed/refractory patients, daratumumab plus lenalidomide (Revlimid)/dexamethasone yielded an 81%...
ASCO 2015: First-in-Class Targeted Drug Daratumumab Is Effective as Single Agent in Heavily Treated Multiple Myeloma
“Daratumumab monotherapy produced unprecedented overall responses that deepened over time” in a phase II trial among patients with heavily treated multiple myeloma, study author Saad Zafar Usmani, MD, reported at a press conference at the 2015 ASCO Annual Meeting. Dr. Usmani, a...
